Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
Regulus Therapeutics (RGLS) PT Lowered to $8 at Wedbush; Clinical Hold Could Be Lifted in Q1 2018 at the Earliest
January 30, 2017 12:22 PM ESTWedbush lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $8.00 (from $13.00) while maintaining a Outperform rating after the FDA requested additional safety data from preclinical experiments and an ongoing trial extends the RG-101 / HCV clinical hold into Q1 2018
Liana Moussatos commented. "... we now anticipate the clinical... More
Wells Fargo Downgrades Regulus Therapeutics (RGLS) to Market Perform
January 30, 2017 6:32 AM ESTWells Fargo downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $2.25 yesterday.
... MoreRegulus Therapeutics (RGLS) PT Lowered to $2 at BMO Capital; Probability of RG-101 Success Down to 25%
January 30, 2017 5:58 AM ESTBMO Capital lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $2.00 (from $5.00) while maintaining a Market Perform rating after the FDA has extended RG-101's clinical hold.
Analyst Matthew Luchini commented, "Our probability of success declines to 25% from 40%, reflecting increased clinical... More
Regulus Therapeutics (RGLS) Shares to Resume Trading at 4:40 PM ET
January 27, 2017 4:18 PM ESTRegulus Therapeutics (NASDAQ: RGLS) Shares to Resume Trading at 4:40 PM ET
... MoreRegulus Therapeutics (RGLS) Reports Continuation of FDA Clinical Hold on RG-101
January 27, 2017 4:11 PM ESTRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug... More
Regulus Therapeutics (RGLS) Halted, News Pending
January 27, 2017 4:06 PM ESTRegulus Therapeutics (NASDAQ: RGLS) Halted, News Pending
... More